For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

Post-Thaw Viability Testing: The Controversy, The Implementation, The Possibilities
Wednesday, May 29, 2024 02:15 PM - 03:15 PM  
Room 208-209
Bioprocessing & Manufacturing
Roundtable
Organized by: ISCT Lab Practices Committee

Moderator
  • Joseph Schwartz, MD, MPH, Moffitt Cancer Center, United States
Panelists
  • Stephan Kadauke, MD, PhD, Cell and Gene Therapy Lab Children’s Hospital of Philadelphia, United States
  • Yongping Wang, MD, PhD, Cell and Gene Therapy Lab Children's Hospital of Philadelphia, United States
  • Elena Maryamchik, MD, MBA, Memorial Sloan Kettering Cancer Center, United States
  • Eapen K. Jacob, MD, Mayo Clinic, United States 

Identify challenges and benefits of implementating post-thaw viability testing programs in clinical cell therapy laboratories

Key Learning Objectives
1. Discuss the importance of testing post-thaw viability for guiding dosing decisions and improving patient outcomes.
2. Share the experience of implementation of post-thaw viability testing programs in a clinical cell therapy laboratory and addressing some of its challenges.
3. Introduce the concept of using the data available on the day of collection to predict post-thaw viability and guide collection decisions. 

Joseph Schwartz
Director, Transfusion Services
Moffitt Cancer Center
Moderator


Eapen Jacob
Medical Director
Mayo Clinic
Panelist


Elena Maryamchik
Cell Therapy Lab Director & Assistant Attending in Transfusion Medicine
Memorial Sloan Kettering Cancer Center
Panelist


Stephan Kadauke
Assistant Professor or Clinical Pathology and Lab Medicine
Children's Hospital of Philadelphia
Panelist


Yongping Wang
Director, Cell and Gene Therapy Lab
Children's Hospital of Philadelphia
Panelist